MBX Biosciences (MBX) reported second-quarter 2026 financial results and corporate updates, including a net loss of $37.1 million, or $0.78 per share basic and diluted. The clinical-stage biopharmaceutical company had $418.6 million in cash, cash equivalents and marketable securities as of June 30, 2026.
The company highlighted progress across its endocrine and metabolic disorder pipeline, including canvuparatide in chronic hypoparathyroidism and obesity candidates MBX 4291, MBX 6180 and MBX 5765.
- Research and development expenses were $31.0 million for the quarter, compared with $17.7 million a year earlier.
- General and administrative expenses were $9.9 million, compared with $4.1 million in the same period of 2025.
- MBX said its cash and investments are expected to fund operations into 2029.
- The Phase 3 oPTimize trial of once-weekly canvuparatide is recruiting, with initiation expected in Q3 2026.
- MBX expects results from the first cohort of the 12-week MAD portion of the MBX 4291 Phase 1 trial in Q4 2026.
- The company nominated MBX 6180 as a GLP-1/GIP/GCG triple agonist prodrug development candidate.
$MBX Insider Trading Activity
$MBX insiders have traded $MBX stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $MBX stock by insiders over the last 6 months:
- P. KENT HAWRYLUK (President & CEO) purchased 18,500 shares for an estimated $525,662
- SALOMON AZOULAY (Chief Medical Officer) sold 370 shares for an estimated $24,334
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MBX Hedge Fund Activity
We have seen 70 institutional investors add shares of $MBX stock to their portfolio, and 67 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 2,920,938 shares (+18550.3%) to their portfolio in Q1 2026, for an estimated $87,189,999
- POLAR CAPITAL HOLDINGS PLC added 1,622,186 shares (+inf%) to their portfolio in Q1 2026, for an estimated $48,422,252
- ECOR1 CAPITAL, LLC removed 1,346,604 shares (-63.4%) from their portfolio in Q1 2026, for an estimated $40,196,129
- CALIGAN PARTNERS LP added 848,590 shares (+inf%) to their portfolio in Q1 2026, for an estimated $25,330,411
- POINT72 ASSET MANAGEMENT, L.P. removed 680,609 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $20,316,178
- DEEP TRACK CAPITAL, LP removed 492,221 shares (-15.1%) from their portfolio in Q1 2026, for an estimated $14,692,796
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 389,947 shares (-27.7%) from their portfolio in Q1 2026, for an estimated $11,639,917
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
